JPRN-UMIN000001253已完成2 期
A randomized trial to asses the effects of hydrogen-rich dissolution water in patients with interstitial cystitis
Koushinkai Hospital0 个研究点目标入组 30 人开始时间: 2008年7月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- •1) Patients who are able to give written informed consent
- •2) Patients who has the characteristic finding under hydraulic distension of the bladder in interstitial cystitis by cystoscope
- •3) It has taken more than 12 weeks after patients took the hydraulic distension of the bladder, and symptom of patients are in stable.
- •4) More than 7 marks in total of Interstitial Cystitis Score in registration
- •5) More than 4 marks in Q4 (degree of bladder pain) in Interstitial Symptom Score
- •6) Age is over 20 years and less than 80 years
- •7) Patients are able to do the following things in this trial; getting good compliance with intaking investigating food and coming to hospital, and writing the diary and the questionnaire accurately by themselves
排除标准
- •1) More than 200ml of an average voided volume at a time before the registration
- •2) Patients with active infection of urinary tract
- •3) Patients with bacterial cystitis within 12 weeks before registration
- •4) Patients with vaginosis
- •5) Patients with calculus of lower urinary tract or urethral diverticulum
- •6) Patients with nephrosis syndrome
- •7) Patients with active genital herpes
- •8) Patients who have operated the surgery in pelvis or its circumference and it has not taken more than 24 hours after the surgery
- •9) Patients with cerebrospinal disease
- •10) Patients with the follow disease or suspected disease; neurogenic bladder, cystitis radiation, tuberculous cystitis, cystitis with BCG, drug associated cystitis
- •11) Start, stop, or change of the dose of the following drugs within 4 weeks after the registration;
- •(a) Antiphlogistic analgetic
- •(b) Antidepressant
- •(c) Anticholinergic drug
- •(d) Antihistamine drug
- •(e) Ataractic drug
- •(f) Drug treatment for frequent urination and acraturesis
- •(g) Steroid drug
- •12) Start or stop new bladder training or diet therapy within 4 weeks befor registration
- •13) Patients who has received bladder instillation therapy, electrical stimulation therapy, or acupuncture and moxibustion within 12 weeks before registration
- •14) Patients with serious hepatic or kidney damage
- •15) Patients with serious heart disease
- •16) Patients with malignant tumors which effect their general status or survival time
- •17) Patients with the history of serious drug-induced adverse effect
- •18) Patients who are in pregnancy, while breast-feeding, or have possibilities of them, or desire pregnancy in test period
- •19) Patients who have taken part in the her clinical research within 12 weeks
- •20) Patients who have taken part in the her clinical research within 12 weeks
- •21) Patients who are inadequate, which their physicians assessed it
研究者
相似试验
已完成
2 期
A randomized trial to assess the effects of hydrogen-ride dissolution water for the patients with mild cognitive impairment (MCI).mild cognitive impairmentJPRN-UMIN000002218Department of Neuropsychiatry, Institute of Clinical Medicine University of Tsukuba120
已完成
2 期
A Randomized trial to assess the effects of hydrogen-rich dissolution water for patients with impaired glucose tolerance or impaired fasting glucoseJPRN-UMIN000001329Kyoto Prefectural University of medicine60
已完成
不适用
Clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2 (COVID-19)07 COVID-19DRKS00022484Poliklinik für Zahnerhaltung und ParodontologieUniversitätsklinikum Regensburg12
已完成
不适用
A pragmatic randomised controlled trial of hydrotherapy and land exercises on global well-being in patients with rheumatoid arthritis (RA).ISRCTN44344800Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
招募中
4 期
Oxygen therapy in severe asthmaAcute asthmaRespiratory - AsthmaACTRN12607000131459Medical Research Institute of New Zealand150